Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire) - Mar 5, 2024 - "In 2024 the Company plans to accomplish the following key business objectives: Obtain FDA IND approval to begin enrollment of ReSPECT-PBC trial for children with high grade glioma and ependymoma."
IND • Brain Cancer • CNS Tumor • Ependymoma • Glioma • Oncology • Solid Tumor
|